China Biopharmaceutical Services Launches 50 Million Yuan BNCT Patient Assistance Plan on July 13

China Biopharmaceutical Services (08037) and Huada Group jointly launched the "BNCT Tumor Patient New Life Assistance Plan" on July 13 at the Shenzhen Huada Space-Time Center. The initiative allocated 5 million yuan in dedicated funds to provide treatment subsidies of up to 100,000 yuan per patient for 50 beneficiaries receiving boron neutron capture therapy (BNCT) at Pengbo (Hainan) Boron Neutron Hospital.

The multi-stakeholder collaboration, involving government guidance, enterprise support, and foundation operations, aims to bridge the affordability gap for BNCT treatment, which typically costs hundreds of thousands of yuan. This program complements the existing commercial insurance product "Good Bor-Pal" and installment financing services, forming a comprehensive payment ecosystem combining insurance, public welfare, and credit solutions to improve patient access to the therapy.